GlassScriptPhysician profile
Orlando Rangel
NPI 1942379466
$3,117.40
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $613 · 2021: $792 · 2022: $363 · 2023: $411 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $787.10 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $710.93 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.66 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $214.12 | 2021-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $196.31 | 2019-2022 | |
| Lilly USA, LLC | $177.19 | 2021-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $124.72 | 2021 | |
| Pfizer INC. | $100.36 | 2019-2023 | |
| Abbott Laboratories | $77.98 | 2020-2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $66.79 | 2019-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $59.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.14 | 2021-2022 | |
| Mylan Specialty L.P. | $50.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.87 | 2021-2022 | |
| Abbvie INC. | $40.56 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.68 | 2019-2022 | |
| Lifescan, INC. | $22.85 | 2023 | |
| Astellas Pharma US INC | $21.04 | 2021 | |
| Shire North American Group INC | $20.48 | 2019 | |
| Biogen, INC. | $17.29 | 2021 | |
| Lundbeck LLC | $13.12 | 2023 | Rexulti |
| Eisai INC. | $12.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlando Rangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.